Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction To Survival Analysis01:18

Introduction To Survival Analysis

938
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
938
Cancer Survival Analysis01:21

Cancer Survival Analysis

821
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
821
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

701
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
701
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

484
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
484
Actuarial Approach01:20

Actuarial Approach

359
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
359
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

713
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
713

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cefazolin for Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia.

The New England journal of medicine·2026
Same author

Spillover Effects in Clinical Trials.

JAMA·2026
Same author

Naloxone and Clinical Outcomes in Suspected Opioid-Associated Out-of-Hospital Cardiac Arrests.

JAMA network open·2026
Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026
Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Deescalation, Discontinuation, and Deimplementation Trials: Evaluating Whether and How to Do Less.

JAMA·2026
Same journal

Surgical and Endoscopic Therapies for GERD.

JAMA·2026
Same journal

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

JAMA·2026
Same journal

"Suturing": Love, Death, and Perfection's Limits.

JAMA·2026
Same journal

What Is Low Back Pain?

JAMA·2026
Same journal

From Silicon Valley to the Vatican-The Expanding Debate on AI Ethics.

JAMA·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Time-to-Event Analysis

Juliana Tolles1, Roger J Lewis2

  • 1Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, California2Los Angeles Biomedical Research Institute, Torrance, California3David Geffen School of Medicine at UCLA, Los Angeles, California.

JAMA
|March 9, 2016
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

869
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Related Experiment Videos

Last Updated: Mar 24, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

869
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K